Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 44 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma Ahead of key Competitiveness Council Meeting of European Research Ministers, ESMO calls for measures supporting a robust clinical research ecosystem in Europe that enables... EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib MOST POPULAR TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer March 7, 2025 Helicobacter Pylori Infection Modifies the Risk of Gastric Cancer Associated with... March 31, 2023 SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... July 27, 2023 Improving research with registered reports May 16, 2022 Load more HOT NEWS Droplet Transmission vs. Airborne… What’s the difference? Experts Propose a Clinical Definition of Acquired Resistance to PD-(L)1 Blockade... Pembrolizumab Combinations Show Promise in mCRPC Should People With Cancer Be Tested for Hepatitis B?
